Merck & Co and Portola agree $470 million deal for Phase II anticoagulant
This article was originally published in Scrip
Executive Summary
Merck & Co has bought the exclusive rights to Portola Pharmaceuticals' investigational oral Factor Xa inhibitor betrixaban. Merck plans to commit up to $470 million to develop and commercialise the anticoagulant for stroke prevention in atrial fibrillation.